Got your eye on a Samsung TV? Right this way, please... But where do you find the right one for you with that much choice? Luckily, we have got you covered. Our team of expert reviewers have tested ...

Samsung Galaxy A3 Duos mobile was launched in February 2015. The phone comes with a 4.50-inch touchscreen display offering a resolution of 540x960 pixels. Samsung Galaxy A3 Duos is powered by a 1.2GHz ...

On January 22, Samsung unveiled the Galaxy S25 and the Galaxy S25 Plus, along with the Galaxy S25 Ultra. To kick things off, the Galaxy S25 models come with Qualcomm's Snapdragon 8 Elite chip in all ...

Android Go Phones List: Check out the list of Android Go Smartphones that includes several Nokia Android Go phones. Google has been teasing Android Go lineup for a long time now and the first Go phone ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...

John­son & John­son is su­ing Sam­sung Bioepis for al­leged­ly breach­ing the terms of a con­tract re­gard­ing the launch of the Ko­re­an biotech’s Ste­lara biosim­i­lar. … ...

Under a settlement inked with J&J in late 2023, Samsung Bioepis and Sandoz got the all-clear to launch their Stelara biosimilar from Feb. 22, 2025. The settlement is one of many J&J has inked over ...

Image credit: Shutterstock/ Michael Vi. Johnson & Johnson (J&J) has sued Samsung Bioepis over a ‘concealed plan’ to supply an unnamed health conglomerate with a private label biosimilar version of ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar. Johnson & Johnson on Monday sued Samsung ...

Johnson & Johnson sued Samsung Bioepis on Monday over that company’s moves to launch an additional biosimilar to J&J’s Stelara with a private label. The complaint and request for a preliminary ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...